Transmural healing evaluated by bowel sonography in patients with Crohn's disease on maintenance treatment with biologics

Inflammatory Bowel Diseases

Volumn 19, Issue 9, 2013, Pages 1928-1934

  Castiglione, Fabiana ^a   Testa, Anna ^a   Rea, Matilde ^a   De Palma, Giovanni Domenico ^a   Diaferia, Maria ^a   Musto, Dario ^a   Sasso, Francesca ^a   Caporaso, Nicola ^a   Rispo, Antonio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Anti TNF ; Crohn's disease; Deep remission; Inflammatory bowel disease; Mucosal healing

Indexed keywords

ADALIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE;

ARTICLE; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HEALING; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MUCOSAL HEALING; PRIORITY JOURNAL; REMISSION; STATISTICAL SIGNIFICANCE; TRANSMURAL HEALING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BIOLOGICAL PRODUCTS; COLONOSCOPY; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; WOUND HEALING; YOUNG ADULT;

EID: 84884620900     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31829053ce     Document Type: Article

References (47)

1. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis. A pathological and clinical entity. JAMA. 1932;99:1323-1329.
2. Mekhjian HS, Switz DM, Melnyk CS, et al. Clinical features and natural history of Crohn's disease. Gastroenterology. 1979;77:898-906.
3. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657.
4. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut. 2011;1178-1181.
5. Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and metaanalysis. Am J Gastroenterol. 2011;106:630-642.
6. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6- mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2010;CD000545.
7. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2005;CD003459.
8. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
9. Orlando A, Armuzzi A, Papi C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2011;43:1-20.
10. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653.
11. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
12. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
13. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts longterm outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15:1295-1301.
14. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010;138:463-468.
15. Panaccione R, Hibi T, Peyrin-Biroulet L, et al. Implementing changes in clinical practice to improve the management of Crohn's disease. J Crohns Colitis. 2012;6:S235-S242.
16. Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut. 2011;60:1754-1763.
17. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102-1111.
18. Hommes D, Colombel JF, Emery P, et al. Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012;6:S224-S234.
19. Travis S, Feagan BG, Rutgeerts P, et al. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. J Crohn's Colitis. 2012;6:S250-S259.
20. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63-70.
21. Paredes JM, Ripolles T, Cortes X, et al. Abdominal sonographic changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease. Dig Dis Sci. 2010;55:404-410.
22. Ripolles T, Martinez MJ, Barrachina MM. Crohn's disease and color Doppler sonography: response to treatment and its relationship with long-term prognosis. J Clin Ultrasound. 2008;36:267-272.
23. Van Assche G, Dignass A, Panes J, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7-27.
24. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212.
25. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512.
26. Fraquelli M, Colli A, Casazza G, et al. Role of US in detection of Crohn disease: meta-analysis. Radiology. 2005;236:95-101.
27. Castiglione F, de Sio I, Cozzolino A, et al. Bowel wall thickness at abdominal ultrasound and the one-year-risk of surgery in patients with Crohn's disease. Am J Gastroenterol. 2004;99;1977-1983.
28. Parente F, Greco S, Molteni M, et al. Modern imaging of Crohn's disease using bowel ultrasound. Inflamm Bowel Dis. 2004;10:452-461.
29. Maconi G, Bollani S, Bianchi Porro G. Ultrasonographic detection of intestinal complications in Crohn's disease. Dig Dis Sci. 1996;41: 1643-1648.
30. Oberhuber G, Stangl PC, Vogelsang H, et al. Significant association of strictures and internal fistula formation in Crohn's disease. Virchows Arch. 2000;437:293-297.
31. Fraquelli M, Sarno A, Girelli C, et al. Reproducibility of bowel ultrasonography in the evaluation of Crohn's disease. Dig Liver Dis. 2008;40: 860-866.
32. Maconi G, Sampietro GM, Parente F, et al. Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intraabdominal abscesses in Crohn's disease: a prospective comparative study. Am J Gastroenterol. 2003;98:1545-1555.
33. Daperno M, Castiglione F, de Ridder L, et al. Results of the 2nd part Scientific Workshop of the ECCO. II: measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484-498.
34. Horsthuis K, Bipat S, Bennink RJ, et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology. 2008;247:64-79.
35. Panés J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther. 2011;34: 125-145.
36. Peloquin JM, Pardi DS, Sandborn WJ, et al. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103:2015-2022.
37. Desmond AN, O'Regan K, Curran C, et al. Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut. 2008;57:1524-1529.
38. European Society of Radiology. White paper on radiation protection by the European Society of Radiology. Insights Imaging. 2011;2:357-362.
39. Castiglione F, Mainenti PP, De Palma GD, et al. Non-invasive diagnosis of small bowel Crohn's disease: direct comparison of bowel sonography and MR-enterography. Inflamm Bowel Dis. 2013;19:991-998.
40. Vos AC, Wildenberg LE, Arijs I, et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis. 2012;18:401-408.
41. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134;929-936.
42. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47-91.
43. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
44. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999;50: 667-671.
45. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease: a prospective multicentre study of 121 cases. Gut. 1994;35:231-235.
46. Modigliani R, Mary JY, Simon JF, et al. Groupe d'Etude Therapeutique des affections inflammatoires digestives. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology. 1990;98:811-818.
47. Olaison B, Sjodahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not endoscopically viewed inflammation. Gut. 1990:31;325-328.